Simcere Pharmaceutical Group Limited (2096.HK) HKSE
9.99
-0.1(-0.99%)
Currency In HKD
- General
- Statistics
- Historical Data
- Profile
- Financials
Simcere Pharmaceutical Group Limited
Address
No. 699-18, Xuanwu Road
Nanjing, 210042
China
Phone
86 25 8556 6666
Website
Sector
Healthcare
Industry
Biotechnology
Employees
6584
First IPO Date
October 27, 2020
Key Executives
| Name | Title | Pay | Year Born |
| Yunshu Zhou | Chief Executive Officer | 0 | 1972 |
| Xi Wang | Vice President & Executive Director | 2.06M | 1983 |
| Yushan Wan | Chief Financial Officer, Joint Company Secretary & Executive Director | 6.98M | 1970 |
| Jinsheng Ren | Co-Founder & Chairman | 9.39M | 1962 |
| Renhong Tang | Executive Director | 11.04M | 1981 |
| Quanfu Feng | Vice President of Marketing | 0 | 1965 |
| Gaobo Zhou | Chief Investment Officer | 0 | 1979 |
| Aik Han Goh | Senior Vice President & Chief Medical Officer | 0 | 1975 |
| Tamas Oravecz | Senior Vice President & Chief Scientific Officer of Simcere Zaiming | 0 | N/A |
| Yongyu Wang | Senior Vice President & Chief Medical Officer of Simcere Zaiming | 0 | N/A |
Description
Simcere Pharmaceutical Group Limited engages in the research, development, manufacture, and sale of pharmaceutical products for distributors and pharmacy chains and other pharmaceutical manufacturers in China. It focusses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. The company's principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; Softan, a rosuvastatin calcium tablet; ZAILIN, an amoxicillin granules/dispersible tablet/capsule; Iremod, an iguratimod tablet; Antine, a diclofenac sodium sustained release capsule/gel; and Orencia, an abatacept injection. It also offers promotion services for pharmaceutical products. Simcere Pharmaceutical Group Limited has a strategic regional licensing partnership with Vivoryon Therapeutics N.V. to develop and commercialize medicines targeting the neurotoxicity amyloid protein N3pE (pGlu-Aß) to treat Alzheimer's disease. The company was founded in 1995 and is headquartered in Nanjing, China.
